What Is Chemoimmunotherapy and How Does It Work?

Chemoimmunotherapy is a cancer treatment strategy that pairs traditional chemotherapy drugs with immunotherapy agents, most commonly immune checkpoint inhibitors. The idea sounds counterintuitive at first: chemotherapy has long been considered immunosuppressive, yet research over the past two decades has shown that certain chemo drugs, given under the right conditions, actually prime the immune system to recognize and attack tumors more effectively. This interplay between cell-killing chemistry and immune activation has produced some of the most significant survival improvements in difficult-to-treat cancers, leading to regulatory approvals across lung cancer, breast cancer, gastric cancer, and several other tumor types.

Why Combining Chemotherapy and Immunotherapy Makes Sense

On the surface, chemotherapy and immunotherapy seem like they should work against each other. Chemotherapy kills fast-dividing cells, which includes immune cells. Immunotherapy depends on a healthy, active immune system. So why combine them? The answer lies in what happens to tumor cells as they die from chemotherapy. Not all cell death is the same. Certain chemo drugs trigger what researchers call immunogenic cell death, a form of dying that essentially sounds an alarm for the immune system.

When tumor cells undergo immunogenic cell death, they release a set of molecular signals known as damage-associated molecular patterns. The key players include calreticulin (a protein that migrates to the cell surface), ATP (the cell’s energy molecule, released into the surrounding tissue), and HMGB1 (a protein normally tucked inside the nucleus). Together, these signals attract and activate dendritic cells, which are the immune system’s scouts. The dendritic cells pick up fragments of the dead tumor, process them, and present them to T cells, effectively teaching the immune system what the cancer looks like.¹ This cascade turns a localized chemical attack on a tumor into something closer to a personalized cancer vaccine.²

Chemotherapy also reshapes the tumor’s local environment in ways that make immunotherapy work better. Many tumors surround themselves with suppressive immune cells that act as bodyguards, blocking the immune system from mounting an effective attack. Several conventional chemo drugs can eliminate or inactivate these suppressive cells, tipping the balance in favor of anti-tumor immunity.³

How Chemotherapy Sets the Stage for Checkpoint Inhibitors

The immunotherapy drugs most commonly paired with chemotherapy are checkpoint inhibitors, which work by removing molecular “brakes” that tumors use to hide from the immune system. One of the most important brakes is PD-L1, a protein that cancer cells display on their surface. When PD-L1 binds to its partner PD-1 on T cells, it tells the T cell to stand down. Checkpoint inhibitors block this handshake, freeing the T cells to attack.

Here is where chemotherapy adds a twist: certain chemo drugs actually increase the amount of PD-L1 on tumor cells. Research on cisplatin in lung cancer patients found that cisplatin-based treatment before surgery significantly increased PD-L1 levels on both tumor cells and immune cells in the surrounding tissue. In that study, roughly a quarter of patients shifted from low to high PD-L1 expression after chemotherapy.⁴ This seems like it should be bad news, since higher PD-L1 means more immune suppression. But if you simultaneously give a checkpoint inhibitor to block that PD-L1, you turn a defensive maneuver by the tumor into a vulnerability. Experiments in mice confirmed this: the combination of cisplatin with anti-PD-L1 antibodies shrank tumors significantly more than either treatment alone.

Similar upregulation of PD-L1 has been observed with other chemo agents across different cancer types, including gastric cancer cell lines treated with multiple chemotherapeutic drugs.⁵ In esophageal squamous cell carcinoma, combination therapy was shown to reduce immune checkpoint engagement between tumor cells and T cells, preventing T cell exhaustion and preserving immune function within the tumor.⁶

Where It All Started

The concept of chemoimmunotherapy predates the checkpoint inhibitor era. Its roots go back to the late 1990s, when researchers began combining the antibody rituximab with the standard chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) for B-cell lymphomas. A 1999 study was the first to demonstrate that this combination was both safe and effective in indolent B-cell lymphoma, producing an overall response rate of 95% with no significant added toxicity compared to CHOP alone.⁷

The approach became standard of care after a landmark trial in elderly patients with diffuse large B-cell lymphoma. Patients receiving CHOP plus rituximab (R-CHOP) had a complete response rate of 76%, compared to 63% with CHOP alone. The addition of rituximab cut the risk of treatment failure by about 40% and reduced the risk of death by roughly a third.⁸ R-CHOP established the proof of concept that merging immune-targeting agents with cytotoxic chemotherapy could produce results neither could achieve independently, and it remains the backbone of lymphoma treatment today.

Modern Clinical Successes Across Cancer Types

The checkpoint inhibitor era has dramatically expanded the reach of chemoimmunotherapy. Its most thoroughly studied application is in non-small-cell lung cancer, which accounts for the majority of lung cancer diagnoses. In a large trial of metastatic non-squamous lung cancer, adding pembrolizumab (a PD-1 inhibitor) to standard platinum-based chemotherapy increased the one-year survival rate from about 49% to roughly 69% and nearly doubled progression-free survival from around 5 months to nearly 9 months.⁹ The benefit held across all levels of PD-L1 expression, meaning even patients whose tumors had low PD-L1 benefited from the combination.

A companion trial in squamous non-small-cell lung cancer showed a similar pattern. Median overall survival went from about 11 months with chemotherapy alone to nearly 16 months with the addition of pembrolizumab, and the risk of death dropped by about a third.¹⁰ These trials led to broad regulatory approvals and made chemoimmunotherapy the default first-line treatment for most patients with advanced lung cancer.

In triple-negative breast cancer, the most aggressive subtype and one historically lacking targeted treatment options, chemoimmunotherapy has gained ground in the neoadjuvant setting, meaning before surgery. Checkpoint inhibitors combined with chemotherapy before tumor removal have produced higher rates of pathological complete response, where no residual cancer is found in the surgical specimen, as well as improved event-free survival.¹¹

Gastric and gastroesophageal junction cancers are another area of active progress. A meta-analysis of perioperative chemoimmunotherapy found that adding immunotherapy to chemotherapy nearly tripled the rate of pathological complete response compared to chemotherapy alone and significantly improved both event-free and overall survival. The benefit was especially pronounced in tumors with microsatellite instability-high status, a molecular feature that makes tumors more visible to the immune system.¹² A separate systematic review reported similar findings, with chemoimmunotherapy improving pathological complete response from about 6% to nearly 18%.¹³

Timing and Sequencing Matter More Than You Might Think

One of the most underappreciated aspects of chemoimmunotherapy is that when you give each component relative to the other can change the outcome. Simply giving both drugs on the same day is the standard approach in most clinical trials, but emerging evidence suggests this may not always be optimal. In a study of patients with non-small-cell lung cancer, delaying the anti-PD-1 antibody by three days after chemotherapy improved the objective response rate from 37% with simultaneous dosing to 68% with sequential dosing. Disease control improved as well, from 81% to 98%.¹⁴

The logic behind this matters. Chemotherapy needs a short window to do its cytotoxic work and trigger immunogenic cell death. If the checkpoint inhibitor comes in too early, the newly activated T cells may themselves be damaged by the chemotherapy. A brief delay allows the chemo to kill tumor cells and release those damage signals, and then the checkpoint inhibitor arrives to amplify the immune response against the freshly exposed tumor antigens. Preclinical research in multiple tumor models has confirmed that getting the timing right can reshape the tumor microenvironment more profoundly than simultaneous treatment.¹⁵ This is an area where current clinical practice may still be catching up with the science.

Side Effects and Safety

Adding immunotherapy to chemotherapy does increase side effects compared to chemotherapy alone, but the increase is more moderate than many patients fear. A review across multiple tumor types found that the combination raised the overall rate of adverse events by about 11% relative to chemotherapy alone. Serious adverse events (grade 3 or higher) increased by roughly 16%, with specific upticks in high-grade diarrhea, shortness of breath, fatigue, rash, and elevated liver enzymes.¹⁶ Crucially, treatment-related mortality did not go up, meaning the combination was not more likely to cause death from side effects.

One of the clinical challenges is distinguishing between side effects caused by the chemotherapy and those caused by the immunotherapy, because they can look similar but require very different management. Chemotherapy-induced nausea, for instance, is treated with anti-nausea drugs. But if your immune system starts attacking your thyroid gland or colon lining because of the checkpoint inhibitor, the treatment is immunosuppressive steroids or hormone replacement. Getting this distinction wrong can mean under-treating or over-treating a side effect. In the neoadjuvant setting for triple-negative breast cancer, a meta-analysis found that chemoimmunotherapy increased the odds of grade 3 or 4 adverse events by about 30% compared to chemotherapy alone, though discontinuation rates were not significantly different between the groups.¹⁷

Predicting Who Will Respond

Not everyone benefits equally from chemoimmunotherapy, and finding reliable biomarkers to predict who will respond remains one of the field’s biggest challenges. PD-L1 expression is the most widely used biomarker, and it does have some predictive value, but it is far from perfect. In esophageal squamous cell carcinoma, for example, PD-L1 status is considered a common but imperfect predictor of response to chemoimmunotherapy.¹⁸ Tumor mutational burden, another commonly discussed biomarker, has similarly failed to reliably predict outcomes with chemoimmunotherapy in lung cancer.¹⁹

One reason these biomarkers fall short is that chemoimmunotherapy changes the tumor environment so dramatically that pre-treatment measurements may not reflect what happens once treatment starts. Research in triple-negative breast cancer has found that patients who respond to chemoimmunotherapy tend to have a higher proportion of certain exhausted-phenotype T cells in their tumors both before and during treatment, while non-responders have more of a different T cell type associated with conventional effector function. Responders also showed enrichment of regulatory T cells during treatment, particularly among those receiving chemotherapy combined with anti-PD-L1 therapy.²⁰ These findings suggest that T cell dynamics within the tumor may eventually prove more useful than static biomarkers measured from a single biopsy, but translating that into routine clinical practice is still years away.

Why Some Tumors Resist

Even with the combination approach, many tumors eventually stop responding. Resistance can emerge through several routes. Some tumors downregulate the molecules that antigen-presenting cells need to recognize them, effectively going invisible again. Others ramp up alternative immune checkpoints that the current drugs do not block, or they recruit fresh waves of suppressive immune cells to replace the ones that chemotherapy cleared out.

An interesting mechanistic finding is that chemotherapy-induced damage to mitochondria inside tumor cells may be one reason chemoimmunotherapy works in the first place. When mitochondria are damaged, they release their own DNA and RNA, which can trigger an immune response within the tumor. Tumors that are better at cleaning up their damaged mitochondria through a process called mitophagy may be better at evading this immune activation, potentially contributing to resistance.²¹ Understanding these escape routes is critical for designing next-generation combinations that can stay one step ahead of the tumor.

The Gut Microbiome Connection

One of the more surprising developments in this field is the growing evidence that the bacteria living in your gut influence how well chemoimmunotherapy works. The gut microbiome has been shown to affect the efficacy and toxicity of both chemotherapy agents and checkpoint inhibitors. For chemotherapy drugs like cyclophosphamide, oxaliplatin, and 5-fluorouracil, gut bacteria can modulate drug metabolism and immune activation. For checkpoint inhibitors targeting PD-1 and CTLA-4, specific bacterial populations appear to correlate with better or worse treatment outcomes.²²

This has spurred interest in actively manipulating the microbiome to improve treatment response. Strategies under investigation include fecal microbiota transplants from treatment responders to non-responders, dietary interventions, and targeted probiotics. The field is still early-stage, and there is growing awareness that the microbiome also influences immune-related side effects, not just efficacy.²³ This means any microbiome-based intervention would need to thread the needle of improving tumor killing without making side effects worse.

Age and Special Populations

A common concern among patients and oncologists alike is whether older adults can tolerate and benefit from chemoimmunotherapy. The immune system weakens with age, which could theoretically blunt the immunotherapy component. However, recent data suggest the combination holds up well across age groups and may even offer outsized benefits to some older patients. In a study of neoadjuvant chemoimmunotherapy for triple-negative breast cancer, women over 70 who received the combination had a greater relative improvement in pathological complete response compared to younger age groups. Overall survival was improved across all ages with chemoimmunotherapy, with the most pronounced survival benefit in women between 50 and 70.²⁴ These findings push back against the assumption that older patients should be excluded from these combinations.

The Financial Reality

The clinical promise of chemoimmunotherapy comes with a practical burden that is easy to overlook in discussions of survival curves. In a study of patients with metastatic non-small-cell lung cancer on immunotherapy or chemoimmunotherapy, about a third reported material financial hardship, nearly two-thirds experienced psychological financial distress, and over half changed their behavior (skipping medications, missing appointments) because of costs. More than half of patients reported hardship in at least two of those domains. Caregiver employment reduction was strongly associated with financial distress; patients whose caregivers had to cut back on work were far more likely to report hardship across multiple domains.²⁵ These are not rare complications that affect a small subset. Financial toxicity is a widespread and under-addressed side effect of modern cancer treatment, and it ripples outward to families and caregivers in ways that clinical trials rarely capture.

Antibody-Drug Conjugates and the Next Evolution

The chemoimmunotherapy playbook is already evolving beyond the combination of conventional chemo plus checkpoint inhibitors. Antibody-drug conjugates, or ADCs, are engineered molecules that attach a cytotoxic chemical payload to an antibody that specifically targets a protein on cancer cells. Think of them as guided missiles: the antibody steers the drug directly to the tumor, and the chemical payload kills the cancer cell on delivery. These are increasingly being combined with checkpoint inhibitors, small-molecule inhibitors, and even CAR-T cell therapies. Clinical studies have shown that ADC-based combinations can improve response rates and progression-free survival across various cancers.²⁶

In non-small-cell lung cancer specifically, the combination of ADCs with immune checkpoint inhibitors is an area of active clinical trial enrollment, reflecting the rationale that ADCs can induce immunogenic cell death in much the same way that conventional chemotherapy does, but with greater precision and potentially fewer off-target side effects.²⁷ Whether ADC-immunotherapy combinations will eventually displace conventional chemoimmunotherapy in some cancer types remains to be seen, but the direction of travel is clear: the next generation of these combinations will be more targeted, more precisely timed, and ideally more tolerable than the regimens in use today.